Biosimilar Antibodies

Fezakinumab is a monoclonal antibody targeting interleukin-22 (IL-22), designed for the investigation of inflammatory conditions including psoriasis and rheumatoid arthritis. This antibody binds specifically to IL-22, a cytokine involved in the regulation of inflammatory responses, offering a valuable tool for researchers studying the pathophysiology and potential therapeutic interventions for these diseases.

Puxitatug is a monoclonal antibody of the immunoglobulin G1-κ class, specifically targeting the human VTCN1 protein, also known as V-set domain-containing T cell activation inhibitor 1, B7 family member H4, B7H4, and B7-H4. This antibody binds selectively to VTCN1, a negative regulator of T cell-mediated immune responses, making it a valuable tool for research in immunology and oncology.

Otlertuzumab (TRU-016) is a humanized monoclonal antibody targeting CD37, designed for use in cancer research. This antibody selectively binds to the CD37 antigen, a protein predominantly expressed on the surface of B cells, making it a valuable tool for studying B-cell malignancies. Otlertuzumab is utilized in various experimental settings to investigate its potential as a therapeutic agent in treating hematological cancers.

Crenezumab (MABT 5102A; RG 7412) is a fully humanized monoclonal antibody designed to target and bind various forms of amyloid beta (Aβ), including soluble, oligomeric, and fibrillar aggregates. This antibody is extensively utilized in the study of Alzheimer's disease, providing a critical tool for researchers investigating the pathogenesis and potential therapeutic interventions for this neurodegenerative disorder.

AMG 305 represents an innovative dual-targeting BiTE (bispecific T-cell engager) molecule, specifically engineered with a half-life extended (HLE) format. This molecule uniquely targets both P-cadherin (CDH3) and mesothelin (MSLN) on tumor cells, in addition to CD3 on T-cells. The design of AMG 305 aims to enhance the therapeutic index in solid tumors by selectively engaging T-cells to tumor cells that co-express CDH3 and MSLN, while minimizing interaction with normal cells that express only one of these antigens. This selective mechanism of action positions AMG 305 as a promising candidate for targeted cancer therapy, especially in settings where both CDH3 and MSLN are overexpressed.

Alirocumab is a human monoclonal antibody that targets and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Alirocumab enhances the liver's capacity to bind and clear low-density lipoprotein cholesterol (LDL-C) from the bloodstream, thereby significantly reducing circulating levels of LDL-C. Additionally, Alirocumab modulates various inflammatory pathways, including the reduction of NLRP3 inflammasome activity and regulation of the Nrf2/HO-1, HMGB1/NF-κB, and Fractalkine/CX3CR1 signaling pathways. These mechanisms contribute to its therapeutic effects in improving atherosclerosis and reducing inflammation. Alirocumab is primarily used in research focused on lipid metabolism disorders, cardiovascular diseases, and inflammatory response modulation.

Gatipotuzumab (PankoMab) is a humanized monoclonal antibody designed to specifically recognize a tumor-specific epitope of mucin-1 (TA-MUC1). This antibody demonstrates potent tumor-specific activity through antibody-dependent cell-mediated cytotoxicity (ADCC), making it a valuable tool for targeted cancer therapy research.

BMS-986021, also known as BMS-986148 antibody, is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Mesothelin, a protein frequently overexpressed in various forms of cancer, making it a valuable tool for oncological research. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 144.46 kDa. For experiments requiring an isotype control, the Human IgG1 kappa Isotype Control is recommended to accurately assess the antibody's specificity and ensure robust experimental results.

The Anti-DC-SIGN/CD209 Antibody is a humanized antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target DC-SIGN/CD209. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of approximately 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for researchers focusing on cellular signaling, immune response modulation, and pathogen recognition studies involving DC-SIGN/CD209.

Ucenprubart is a human IgG4κ monoclonal antibody targeting CD200R1. For optimal experimental control, it is recommended to use Human IgG4 kappa as an isotype control.

Maslimomab is a murine-derived monoclonal antibody specifically designed to target the T-cell receptor. This antibody functions as an immunosuppressive agent, making it a valuable tool for research into T-cell mediated immune responses and potential therapeutic applications in immune-related disorders.

Enlimomab (BI-RR 0001) is a murine IgG2a monoclonal antibody that targets human Intercellular Adhesion Molecule 1 (ICAM-1). This antibody functions by inhibiting leukocyte adhesion to vascular endothelium, effectively reducing leukocyte extravasation and subsequent inflammatory tissue damage. Due to its anti-inflammatory properties, Enlimomab is particularly useful in research focused on stroke and related inflammatory processes.

Alnuctamab (EM901) is a humanized, asymmetric two-arm immunoglobulin G (IgG) T-cell engager (TCE) designed to facilitate targeted immune responses. This bi-specific antibody selectively binds to the B-cell maturation antigen (BCMA) and CD3, a critical component of the T-cell receptor complex. Alnuctamab is primarily utilized in immunological research to study and manipulate T-cell mediated responses against cells expressing BCMA, making it a valuable tool in the investigation of immune therapies.

Bavunalimab is a bispecific monoclonal antibody targeting CTLA-4 and LAG-3, designed for the dual inhibition of these immune checkpoint inhibitors. This humanized antibody promotes T-cell activation, demonstrated in NSG mouse models, making it a valuable tool for investigating immune responses in oncology research. Bavunalimab is specifically developed for studies focusing on the modulation of immune checkpoints in cancer therapy.

MEDI-1814 is a fully human IgG1 monoclonal antibody designed to target the C-terminus of amyloid beta (Aβ) 42 peptide. This antibody specifically binds to circulating Aβ peptides, facilitating their removal and preventing their aggregation into neurotoxic oligomers. MEDI-1814 is primarily utilized in research focused on the pathogenesis and potential treatments of Alzheimer's disease. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Romlusevimab (BRII-198) is a recombinant human IgG1 monoclonal antibody designed to specifically neutralize the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This targeted mechanism of action facilitates the inhibition of viral entry into host cells, offering potential therapeutic benefits in the treatment and prevention of COVID-19. Romlusevimab’s specificity and neutralizing capability make it a valuable tool in coronavirus research and therapeutic development.

Danvilostomig is a monoclonal antibody designed to target CTLA4 and PDCD1, key immune checkpoint proteins. This antibody is utilized in the study of immune checkpoint regulation and has potential applications in immunotherapy research, particularly in the context of cancer and autoimmune diseases. Danvilostomig's dual specificity allows for comprehensive investigation into the mechanisms of T-cell regulation and immune tolerance.

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular domain of glycoprotein NMB (GPNMB), which is overexpressed in certain human breast cancers and melanomas. This antibody can be conjugated with the cytotoxic drug monomethyl auristatin E to create glembatumumab vedotin, an antibody-drug conjugate (ADC) designed to deliver antitumor agents directly to cancer cells. Glembatumumab vedotin demonstrates significant antitumor activity by exploiting the specificity of the antibody to direct cytotoxic activity to GPNMB-expressing tumor cells, thereby minimizing systemic toxicity. This mechanism positions it as a promising therapeutic option in the treatment of GPNMB-expressing malignancies.

Praluzatamab is a monoclonal antibody specifically designed to target the activated leukocyte cell adhesion molecule (ALCAM), also known as CD116. This antibody has been engineered to facilitate the development of antibody-drug conjugates, such as Praluzatamab ravtansine, enhancing its utility in targeted cancer therapy. Praluzatamab is primarily utilized in oncological research, where it serves as a critical tool in the investigation of cancer pathogenesis and the development of novel therapeutic strategies.

Rademikibart (CBP-201) is a human monoclonal antibody specifically designed to target IL-4Rα, exhibiting a high binding affinity with a dissociation constant (K_D) of 20.7 pM for human IL-4Rα epitopes. This antibody is characterized by its species specificity, as it does not interact with IL-4Rα from non-human species. Rademikibart effectively inhibits both IL-4 and IL-13-mediated STAT6 signaling pathways, as well as TF-1 cell proliferation and TARC production in peripheral blood mononuclear cells (PBMCs). This antibody is particularly relevant for research into moderate-to-severe Th2-mediated inflammatory diseases, providing a valuable tool for elucidating disease mechanisms and potential therapeutic targets.

Urabrelimab (SRF231) is a fully human monoclonal antibody targeting CD47. It effectively inhibits the interaction between CD47 and signal-regulatory protein alpha (SIRPα), a critical pathway involved in evading phagocytosis by immune cells. This blockade can promote the engulfment and elimination of cancer cells, making it a valuable tool for oncology research.

Camoteskimab (AVTX-007) is a fully humanized, high-affinity monoclonal antibody targeting interleukin-18 (IL-18). By specifically binding to IL-18, Camoteskimab effectively inhibits the interaction between IL-18 and its receptor, thereby modulating the inflammatory response. This antibody is particularly valuable in research focused on cardiovascular and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma, providing a potent tool for investigating the pathological roles of IL-18 in these conditions.

Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC.

Serplulimab (HLX10) is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. This antibody is designed for use in research focused on small cell lung cancer, providing a valuable tool for investigating the role of the PD-1/PD-L1 pathway in cancer immunology and potential therapeutic interventions.

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody that specifically targets the fibroblast activation protein (FAP). This antibody is utilized in research focusing on colorectal cancer and non-small cell lung cancer (NSCLC), providing a valuable tool for investigating the role of FAP in tumor progression and response to therapy.

The Anti-PCSK9 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is ideal for research focused on the regulation of LDL cholesterol levels and cardiovascular disease mechanisms.

GSK-2330811 is a humanized IgG1 monoclonal antibody specifically designed to target Oncostatin M (OSM). This antibody is primarily utilized in research focused on diffuse cutaneous systemic sclerosis (dcSSc). For experimental control purposes, Human IgG1 kappa serves as the appropriate isotype control for GSK-2330811.

Quetmolimab is a humanized monoclonal antibody targeting CX3CL1, a chemokine known for its role in modulating chemotaxis and cell adhesion. This antibody is designed for precision in binding and neutralizing CX3CL1, making it a valuable tool for research into inflammatory responses and immune cell migration.

Izastobart is a human IgG1 λ2 monoclonal antibody targeting C5AR1. For accurate experimental controls, it is recommended to use Human IgG1 lambda2 as an isotype control.

Maridebart is a monoclonal antibody of the human immunoglobulin G1-kappa subclass, specifically targeting the gastric inhibitory polypeptide receptor (GIPR). This antibody binds selectively to GIPR, a receptor involved in glucose homeostasis and lipid metabolism, making it a valuable tool for research in metabolic disorders and diabetes.

Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). The absence of fucose on this antibody significantly enhances its Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. This antibody effectively blocks the interaction between B-cell Activating Factor (BAFF) and its receptor BAFF-R, thereby inhibiting the BAFF-mediated apoptotic protection. This makes Ianalumab (FUT8-KO) a valuable tool for research into BAFF-R related signaling pathways and potential therapeutic interventions in autoimmune diseases and malignancies where BAFF and BAFF-R interactions play a critical role.

Vobramitamab is a humanized monoclonal antibody targeting B7-H3, conjugated to the prodrug seco-DUBA through a cleavable linker to create the antibody-drug conjugate (ADC) MGC018. This ADC has demonstrated potent antitumor efficacy in preclinical models across a variety of cancers, including breast, ovarian, lung cancer, and melanoma. MGC018's design allows for targeted delivery of the cytotoxic agent to tumor cells, minimizing systemic exposure and enhancing therapeutic potential.

Crebankitug is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets the IL7 receptor (IL7R). For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control. This antibody is designed for use in research studies to investigate IL7R-mediated signaling pathways and potential therapeutic applications targeting IL7R.

The Anti-CHI3L1 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CHI3L1. This antibody is comprised of a human IgG1 type heavy chain and a human kappa-type light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended as the isotype control for this antibody. This product is essential for researchers focusing on the biological pathways and disease associations involving CHI3L1.

Pulocimab is a monoclonal antibody targeting VEGFR2 (vascular endothelial growth factor receptor 2), designed for use in cancer research. This antibody binds specifically to VEGFR2, inhibiting its signaling pathways, which are critical for tumor angiogenesis and growth. Pulocimab offers a valuable tool for researchers studying the molecular mechanisms of cancer progression and exploring potential therapeutic strategies targeting angiogenesis.

Vipalanebart is a human IgG4 κ monoclonal antibody targeting ADCYAP1R. For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody provides a valuable tool for the specific detection and characterization of ADCYAP1R in various research applications.

Blinatumomab, also known as Anatumomab, is a bispecific monoclonal antibody designed to simultaneously engage two distinct epitopes: CD3E on T cells and CD19 on B cells. This unique dual-binding capability facilitates the redirection of T cells to target and eliminate CD19-expressing B cells. Blinatumomab is primarily utilized in research focused on the treatment and understanding of acute lymphoblastic leukemia (ALL), offering significant insights into therapeutic strategies and disease management.

Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody designed to target CD147, a cell surface antigen. This antibody facilitates cell death via complement-mediated lysis. It is primarily utilized in the study of graft-versus-host disease (GVHD), offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions of this condition.

AGS-67E is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TSPAN26/CD37. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 143.44 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended. AGS-67E is applicable for a range of research studies focusing on the biological functions and therapeutic targeting of TSPAN26/CD37.

The Anti-EphA2 Antibody (1C1), also known as MEDI-547, is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the EphA2 receptor, a critical component involved in various cellular processes including angiogenesis, neurogenesis, and cancer progression. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, and has a predicted molecular weight of 146.68 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Pavurutamab (AMG-701) is a bispecific T-cell engager that targets both CD3 on T-cells and B-cell maturation antigens (BCMA) on plasma cells. This molecule is engineered with an extended half-life derivative of Pacanalotamab, enhancing its stability and duration of action. The Fc region of Pavurutamab has been modified to incorporate molecules that optimize its pharmacokinetic properties, ensuring sustained efficacy. This biologic is primarily investigated for its potential therapeutic applications in the modulation of immune responses and as a treatment for multiple myeloma (MM).

Ponsegromab (PF 06946860) is a potent, selective humanized monoclonal antibody targeting GDF15, designed to inhibit its interaction with the GFRAL receptor. By binding to GDF15, Ponsegromab effectively prevents GDF15 from engaging with the GFRAL receptor, thereby obstructing the GDF15/GFRAL-mediated signaling pathway. This antibody exhibits significant anti-cachexia activity, making it a valuable tool for research in oncology settings where cachexia is prevalent.

Mirvetuximab (M9346A) is a monoclonal antibody targeting FOLR1 (folate receptor 1), specifically designed to bind to folate receptor alpha (FRα). This antibody serves as the crucial component of the antibody-drug conjugate (ADC) Mirvetuximab soravtansine, which is utilized in the investigation of ovarian and other FRα-positive cancers. Mirvetuximab soravtansine's mechanism focuses on delivering cytotoxic agents directly to cancer cells expressing FRα, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is essential for research aimed at developing targeted therapies for FRα-expressing tumors.

Carotuximab (TRC105) is an IgG1 monoclonal antibody designed to inhibit endoglin (CD105), a critical component of the Smad signaling pathway. This antibody exhibits both immunomodulatory and antineoplastic properties, making it a valuable tool in cancer research and therapy development. Carotuximab targets endoglin-expressing cells, thereby interfering with cellular processes essential for tumor growth and angiogenesis.

Patecibart is a humanized IgG4-kappa monoclonal antibody designed to specifically target and inhibit the endothelin receptor type A (EDNRA). As an endothelin receptor antagonist, it plays a critical role in modulating vascular function by blocking the binding of endothelin-1 to its receptor, potentially alleviating conditions associated with vascular dysfunction and constriction. This antibody is pivotal for research focused on cardiovascular diseases, pulmonary arterial hypertension, and other endothelin-related pathologies.

Gocatamig is a chimeric humanized antibody designed with a single-chain variable fragment-heavy-lambda (scFv-heavy-lambda)-VH-VH' configuration. It specifically targets CD3E, ALB, and DLL3, making it suitable for advanced research applications that investigate cellular processes involving these proteins. This antibody's unique structure and specificity are ideal for studies in immunology and oncology, particularly in the modulation of immune responses and the investigation of cancer cell dynamics.

The Anti-TNFSF2/TNFa Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets TNFSF2/TNFa, a pivotal cytokine involved in systemic inflammation and the acute phase response. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, it is recommended to use the Human IgG1 kappa, Isotype Control. This antibody is suitable for a range of research applications, providing a critical tool for the study of TNF-alpha's role in disease pathogenesis and therapeutic interventions.

ATG-031 is a humanized monoclonal antibody targeting CD24, designed to enhance the immune system's ability to combat cancer. By inhibiting CD24-mediated "don't eat me" signals, ATG-031 promotes macrophage-mediated phagocytosis, leading to the destruction of cancer cells. This antibody is applicable in research focused on both hematological malignancies and solid tumors, providing a valuable tool for studies aimed at understanding and potentially disrupting cancer cell survival mechanisms.

PF-07062119 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to specifically target and inhibit guanylate cyclase 2C (GUCY2C). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This product is essential for research focused on the role of GUCY2C in various biological processes and disease states.

Dectrekumab (QAX576) is a human monoclonal antibody designed to selectively target interleukin-13 (IL-13). This antibody has demonstrated efficacy in significantly reducing intraepithelial esophageal eosinophil counts and normalizing dysregulated disease-related transcripts in patients with Eosinophilic Esophagitis (EoE). Its sustained activity makes it an invaluable tool for research focused on inflammation and immunological disorders.